Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia

Logo poskytovatele
Logo poskytovatele

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.
Autoři

MALČÍKOVÁ Jitka STAŇO KOZUBÍK Kateřina TICHÝ Boris KANTOROVÁ Barbara PAVLOVÁ Šárka TOM Nikola RADOVÁ Lenka ŠMARDOVÁ Jana PARDY Filip DOUBEK Michael BRYCHTOVÁ Yvona MRÁZ Marek PLEVOVÁ Karla DIVÍŠKOVÁ Eva OLTOVÁ Alexandra MAYER Jiří POSPÍŠILOVÁ Šárka TRBUŠEK Martin

Rok publikování 2015
Druh Článek v odborném periodiku
Časopis / Zdroj Leukemia
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www http://www.nature.com/leu/journal/v29/n4/pdf/leu2014297a.pdf
Doi http://dx.doi.org/10.1038/leu.2014.297
Obor Onkologie a hematologie
Klíčová slova LRF CLL4 TRIAL; TERM-FOLLOW-UP; GENOMIC ABERRATIONS; SURVIVAL; FLUDARABINE; P53; CYCLOPHOSPHAMIDE; INACTIVATION; DYSFUNCTION; RESISTANCE
Přiložené soubory
Popis In chronic lymphocytic leukemia (CLL), the worst prognosis is associated with TP53 defects with the affected patients being potentially directed to alternative treatment. Therapy administration was shown to drive the selection of new TP53 mutations in CLL. Using ultra-deep next-generation sequencing (NGS), we performed a detailed analysis of TP53 mutations' clonal evolution. We retrospectively analyzed samples that were assessed as TP53-wild-type (wt) by FASAY from 20 patients with a new TP53 mutation detected in relapse and 40 patients remaining TP53-wt in relapse. Minor TP53-mutated subclones were disclosed in 18/20 patients experiencing later mutation selection, while only one minor-clone mutation was observed in those patients remaining TP53-wt (n=40). We documented that (i) minor TP53 mutations may be present before therapy and may occur in any relapse; (ii) the majority of TP53-mutated minor clones expand to dominant clone under the selective pressure of chemotherapy, while persistence of minor-clone mutations is rare; (iii) multiple minor-clone TP53 mutations are common and may simultaneously expand. In conclusion, patients with minor-clone TP53 mutations carry a high risk of mutation selection by therapy. Deep sequencing can shift TP53 mutation identification to a period before therapy administration, which might be of particular importance for clinical trials.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.